Navigation Links
Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
Date:9/22/2008

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Napo Pharmaceuticals (LSE: NAPL/NAPU) today announces positive clinical data on the effectiveness of crofelemer from a study for CRO-ID in treating severely ill cholera patients in conjunction with an antibiotic and rehydration therapy.

A double-blind placebo-controlled study was conducted in one hundred (100) patients with confirmed severe cholera. Patients were randomized to placebo or 125 mg crofelemer every 6 hours or 250 mg crofelemer every 6 hours in a 1:2:2 randomization scheme. This single center trial was conducted at the International Centre for Diarrhoeal Disease Research (ICDDR, B) in Dhaka, Bangladesh, popularly known as the "cholera hospital" for the state-of-the-art treatment of cholera patients.

The purpose of the trial was to obtain a therapeutic proof-of-concept in the treatment of cholera, by a reduction in the life-threatening fluid loss characteristic of cholera infection. In addition to receiving crofelemer, all patients received a single oral dose of azithromycin and rehydration therapy. These severely ill cholera patients, even when receiving the antibiotic azithromycin and rehydration therapy (but not crofelemer), averaged approximately 8.5 liters of stool volume output during the first 24 hour period. The primary endpoint in this study was the reduction in stool volume output normalized to the body weight of the cholera patients.

Following the exclusion of three outlier patients, the data demonstrates that a crofelemer dose of 125 mg every 6 hours reduced the amount of stool volume output normalized to body weight by 32% (p=0.028, Mann-Whitney test) in the first 6 hour period (0-6 hours). A 31% reduction in normalized stool volume output was also observed during the first 12 hour period (0-12 hours) with crofelemer 125 mg every 6 hours (p=0.072, Mann-Whitney test). The higher dose of crofelemer (250 mg every 6 hours) also showed a trend towards significance in the first 12
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
3. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
4. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
5. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
6. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
7. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
8. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
11. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015  Later this week, Cardinal Health Specialty ... economic outcomes research (HEOR) studies that reinforce the ... value-based reimbursement strategies.   Dr. ... officer of Cardinal Health Specialty Solutions, says that ... for more than a decade that clinical trials ...
(Date:5/27/2015)... YORK , May 27, 2015  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... Conference on Monday, June 1, 2015 at the Luxe ... . The presentation by Michael ... corporate development, is scheduled to begin at 2:00 p.m. ...
(Date:5/27/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... focused on oncology with an emphasis on the ... findings from its recent three-day Key Opinion Leader ... Company,s percutaneous hepatic perfusion (PHP) therapy for the treatment ... Paris and included more ...
Breaking Medicine Technology:New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 2New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 3Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference 2Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference 3Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer Patients 2Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer Patients 3Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer Patients 4Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer Patients 5
(Date:5/27/2015)... Florida (PRWEB) May 27, 2015 ... impartial customer satisfaction surveys in the multiple services ... poll to determine the highest ranked Electronic Health ... part of a special research focus on implemented ... announced those software vendors with the highest scores ...
(Date:5/27/2015)... AR (PRWEB) May 27, 2015 ... today announce a partnership to provide CMSA's Career ... community. This collaboration seeks to strengthen the case/care ... through CMSA’s CKP program. The mutually beneficial agreement ... identifying individual skills of talent in the healthcare, ...
(Date:5/27/2015)... Difass USA, a modern supplement brand committed ... first three flagship products, Dormiva™, Relaxiva™ and Reminiva™. All ... http://www.difassusa.com . , A restful night’s sleep is ... people struggle with getting the full amount of sleep ... designed to help you fall asleep and stay asleep, ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 On ... North-based advertising agency, will partner with LifeSource to host ... event will take place in a LifeSource donor coach ... a.m. to 4:00 p.m. , Demand for whole blood ... in Illinois, during the summer months. LifeSource requires approximately ...
(Date:5/27/2015)... 27, 2015 Genius Monkey is pleased ... programmatic marketing technology, they have boosted sales for the ... a regional level for seven Utah-based dealers. , ... television and radio media. In 2014 the Utah Honda ... of Genius Monkey , shifted their marketing campaigns ...
Breaking Medicine News(10 mins):Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2
... intramuscular injection, study says , , THURSDAY, Feb. 7 ... for delivering DNA vaccines than intramuscular injection, a new ... Genetic Vaccines and Therapy , researchers at the ... protein from the human papillomavirus (HPV), which causes cervical ...
... With Mass ... Production Starting in May, 2008, HERZLIYA, Israel, February ... the availability of a,stand-alone chip that integrates Dblur,s groundbreaking Software ... Lens(TM),camera modules of up to 3.2Mp. Samples are currently available ...
... Presidential Campaign ... Issue, WEST PALM BEACH, ... and small, in promoting the fact,that they hire and employ only legally documented ... online and,offline, the fact that they exclusively employ legal workers., Companies will ...
... MDTH ), a healthcare provider focused on ... of cardiovascular,disease, today announced its operating results for ... First Quarter 2008 Results, During its ... of Harlingen Medical Center ("HMC"). As part of ...
... - DRAXIS Health Inc. (TSX:,DAX); (Nasdaq: DRAX ... and,the year ended December 31, 2007. Results for ... quarter of 2006 were impacted by lower product ... business,segments, compounded by the significantly stronger Canadian dollar ...
... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced that it ... CEO & Investor Conference February 13, 2008 ... Chairman and CEO, http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NUVO&item_id=1752425 , Fourth Quarter ... Call & Webcast February 27, 2008 4:30 p.m. ...
Cached Medicine News:Health News:Tattooing Best Way to Deliver DNA Vaccines 2Health News:Dblur Announces the Availability of a Software Lens(TM) Enabled Chip 2Health News:Dblur Announces the Availability of a Software Lens(TM) Enabled Chip 3Health News:Legal Employer Provides Companies with Competitive Edge by Assuring Consumers that Workers are Legally Documented 2Health News:MedCath Corporation Reports First Quarter Earnings 2Health News:MedCath Corporation Reports First Quarter Earnings 3Health News:MedCath Corporation Reports First Quarter Earnings 4Health News:MedCath Corporation Reports First Quarter Earnings 5Health News:MedCath Corporation Reports First Quarter Earnings 6Health News:MedCath Corporation Reports First Quarter Earnings 7Health News:MedCath Corporation Reports First Quarter Earnings 8Health News:MedCath Corporation Reports First Quarter Earnings 9Health News:MedCath Corporation Reports First Quarter Earnings 10Health News:MedCath Corporation Reports First Quarter Earnings 11Health News:MedCath Corporation Reports First Quarter Earnings 12Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 2Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 3Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 4Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 5Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 6Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 7Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 8Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 9Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 10Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 11Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 12Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 13Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 14Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 15Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 16Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 17Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 18Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 19Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 20Health News:DRAXIS Health Reports Fourth Quarter and Year End Results 21
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... continues the "Consensus Concept" approach to design ... experience of a Scientific Advisory Board. The ... incorporates state-of-the-art features. Consensus Knee implants are ... stability and allow near normal kinematics. The ...
Medicine Products: